(Q50623333)

16 March 2018

title

Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. (English)

1 reference

16 March 2018

1 reference

Dillioglugil O

1

1 reference

16 March 2018

Leibman BD

2

1 reference

16 March 2018

Kattan MW

3

1 reference

16 March 2018

Seale-Hawkins C

4

1 reference

16 March 2018

Wheeler TM

5

1 reference

16 March 2018

Scardino PT

6

1 reference

16 March 2018

language of work or name

English

0 references

publication date

1 July 1997

1 reference

16 March 2018

published in

Urology

1 reference

16 March 2018

volume

50

1 reference

16 March 2018

issue

1

1 reference

16 March 2018

page(s)

93-99

1 reference

16 March 2018

Total prostatectomy for localized prostatic cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900106-4

7 January 2021

Radical Surgery for Prostatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900106-4

7 January 2021

Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900106-4

7 January 2021

Long-Term (15 Years) Results After Radical Prostatectomy For Clinically Localized (Stage T2c Or Lower) Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900106-4

7 January 2021

Can patients with breast cancer be cured of their disease? A sample of the M. D. anderson Hospital experience

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900106-4

7 January 2021

The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900106-4

7 January 2021

Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900106-4

7 January 2021

Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900106-4

7 January 2021

The Incidence and Significance of Detectable Levels of Serum Prostate Specific Antigen After Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900106-4

7 January 2021

Recurrent Prostate Cancer Despite Undetectable Prostate Specific Antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900106-4

7 January 2021

Can Radical Prostatectomy Alter the Progression of Poorly Differentiated Prostate Cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900106-4

7 January 2021

Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance program.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900106-4

7 January 2021

Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900106-4

7 January 2021

Patterns of Care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900106-4

7 January 2021

Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900106-4

7 January 2021

Current controversies in the management of localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900106-4

7 January 2021

Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900106-4

7 January 2021

Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900106-4

7 January 2021

Use of the hazard rate to schedule follow-up exams efficiently. An optimization approach to patient management

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900106-4

7 January 2021

10.1016/S0090-4295(97)00106-4

Identifiers

DOI

1 reference

16 March 2018

PubMed ID

9218025

1 reference

16 March 2018